An interesting finding here is that the high dose (3 mg/kg) of A2A antagonist reduced the amount of adenosine available to cause neuromodulation or neuroprotection during cerebral ischemia/reperfusion. This evidence concerns the gene IGKV2D-29 and brain ischemia.